T1	Intervention 131 182	randomised, controlled, double-blind, phase 2 trial
T2	Intervention 0 47	Ganitumab with either exemestane or fulvestrant
T3	Intervention 539 552	phase 2 trial
T4	Intervention 786 1062	central randomisation schedule to receive intravenous ganitumab 12 mg per kg bodyweight or placebo in combination with open-label intramuscular fulvestrant (500 mg on day 1, then 250 mg on days 15, 29, and every 28 days) or oral exemestane (25 mg once daily) on a 28-day cycle
